Category Archives: Stem Cell Medicine

Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit – Yahoo Finance

CEO Sandy Solmon to Present on Celavies Stem Cell Therapies at Upcoming Conferences in New York and Barcelona

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled "Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients," at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

The poster shows five-year follow-up data that expands on the exploratory clinical data in 7 PD patients with four-year follow-up published in Cell Transplantation in 2018. Oleg Kopyov, Executive Vice President and Chief Scientific Officer at Celavie, presented the poster on-site at the Miami Hyatt Regency.

In the results at one year after cell grafting, all but two of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. At five-year evaluation, Unified Parkinsons Disease Rating Scale III (UPDRS III) scores remained better than at baseline in 4/7 patients in the OFF condition and in 5/7 patients in the ON condition. None of the patients showed unwanted motor disturbances (dyskinesias), tumor formation, or any detectable immune responses to the grafted cells.

"We are excited that the five-year data for our exploratory clinical trial suggest that the neural progenitor cells are able to stop or slow down the motor deterioration in Parkinsons patients that one would expect to see in this timespan, showing continued improvement even compared to the fourth year," said Oleg Kopyov. "We anticipate filing an IND with the FDA for a Phase I U.S. trial in patients with moderate to advanced Parkinsons disease this year."

In addition, Sandy Solmon, Celavies CEO, will deliver presentations at two upcoming international industry conferences:

Ms. Solmon will discuss Celavies application of the companys human undifferentiated allogeneic pluripotent stem cells in Parkinsons disease, as well as pre-clinical data in cerebellar ataxia and upcoming milestones. To schedule a meeting with Celavie Biosciences at these conferences, please contact: Mary Beth Cicero at

About the World Stem Cell Summit

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit:

About Celavie Biosciences

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at

View source version on


Hannah MongeonLaVoieHealthScience(617)

Read the original post:
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Yahoo Finance

The Brave New World of Organoids – North Forty News

PHOTO COURTESY OF ROANE STATE COMMUNITY COLLEGE, TN: Typical nervous tissue that can now be grown as organoids in the lab.

Bio Bites

By R. Gary Raham

One of the big scientific news stories of 2019 involved the use of organoids to help fight disease, and to learn more about how embryos build entire human beings from one fertilized egg cell. The term organoids has a science fictiony sound to it. A title like Attack of the organoids wouldnt be out of place in an SF library. Actually, the ability to create specialized tissuelike bundles of brain neurons that hook together to transmit nerve impulsescan raise a few hairs on ones neck. But organoids do hold great promise for curing diseases, broadening our understanding of development, and personalizing medical treatments.

Stem cells allow scientists to build organoids. Stem cells are like major subcontractors produced by embryos to build the various organs and organ systems we depend on. These pluripotent cells (cells that can differentiate in many ways) can produce brain, kidney, lung, intestinal, stomach, and liver tissue. The tissue clumps produced tend to be smallroughly the size of a peapartly because they dont have access to the circulatory system the body uses to provide oxygen and nutrients and remove wastes. Scientists have to provide work-arounds to keep organoids alive and functioning.

One of the amazing things about organoids is that they self-organize into recognizable tissues without input from an entire body. Take brain cells for example. The neurons produced by stem cells link up and form networks that are capable of transmitting nerve impulses like an intact, complete brain. One leading researcher in this field of study is Alysson Muotri, a biologist at University of California San Diego School of Medicine. His website is He also has a fascinating series of YouTube videos called Building The Brain With Alysson Muotri. Muotri was senior author on a paper in 2019 in Cell Stem Cell. His lab was able to nurture the growth of brain organoids for many months. After four months electrical activity in the organoids began to increase exponentially. By twenty-five weeks, a computer program had a hard time distinguishing between brain wave patterns produced by organoids and pre-term babies.

Brain tissue organoids also hold promise for studying conditions like autism in human beingsa kind of neurological condition marked by differences in learning styles, repetitive motions, and sometimes difficulty with language and communication. The Harvard Stem Cell Institute is also studying how the Zika virus associates with microcephaly (small brain syndrome) during early embryo development.

Someday, scientists may be able to routinely take stem cells from individuals and test the efficacy of drugs on that persons liver cells, for example, to make sure those drugs wont produce harmful or fatal effects.

The brave new world of organoids is comingand not just in the next SF novel you read.

Go here to read the rest:
The Brave New World of Organoids - North Forty News

Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status – GlobeNewswire

MIAMI, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine Inc. (OTCPK:BPSR) (the Company) is pleased to provide shareholders and the investment community with an update on operations since its filing on November 1, 2018 of the Companys Annual Report on Form filing of Form 10-K for the year ended October 31, 2017, as well as the status of becoming fully compliant with SEC reporting obligations.

The Company is diligently working to complete its Quarterly Reports on Form 10-Q for the quarters ended January 31, 2018, April 30, 2018 and July 31, 2018 and its Annual Report on Form 10-K for the year ended October 31, 2018. In August 2019, the Company engaged Marcum LLP as its independent registered public accounting firm. The Company expects these reports to be completed and filed during the first calendar quarter of 2020. Following completion and filing of these reports, the Company expects to promptly proceed to preparation and filing of its Quarterly and Annual Reports for the fiscal year ended October 31, 2019, with the objective of becoming current in its SEC reporting requirements as soon as possible.

Since November 2018, the Company has remained focused on research and development activities and sale and distribution of anti-aging and cellular therapy derived products.

In February 2019, the Company recommenced its efforts to once again operate a perinatal tissue bank processing laboratory in Miami, Florida for the purpose of performing research and development and the manufacturing and processing of anti-aging and cellular therapy derived products. This new laboratory facility became operational in May 2019 and during the same period, the Company began producing products that are now being sold and distributed to its customers.

In addition, the Company has created what it believes is a world class research, medical and scientific advisory team. We believe that our team is one of the most qualified and industry reputable teams assembled to adequately address the current and expected future medical and regulatory challenges facing the Company and overall industry and to provide leadership in the ongoing development of superior quality products for use in the health care industry.

The Company has actively taken steps to assure that it meets compliance with current and anticipated United States Food and Drug Administration (FDA) regulations expected to be enforced beginning in November 2020 requiring that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (HCT/Ps) can only be sold pursuant to an approved biologics license application (BLA). On July 14, 2019, the Company received Institutional Review Board (IRB) approval to proceed with two pilot studies in connection with the Companys efforts to obtain Investigation New Drug (IND) approval from the FDA and commence clinical trials in connection with the use of the Companys products and related treatment protocols for specific indications. The Company is aggressively pursuing efforts to obtain the aforementioned IND approvals and commence and complete those clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available.

In an effort to increase sales and mitigate anticipated near future restrictions expected to be imposed by the FDA with respect to the use and distribution of Section 351 designated biologics, the Company is seeking to develop sales and distribution channels outside of the United States. In addition, the Company is focusing its efforts on developing other leading edge product offerings that would not fall within the FDA regulations for requiring a BLA license for U.S. manufacture and sale.

As a result of the Companys expected future increase in processing requirements and to enable it to perform certain advanced research and development activities, the Company is currently in negotiations to relocate its laboratory facility during the second calendar quarter of 2020 to a larger ISO 7 classified research and development and processing facility.

The Company has also been actively developing and expanding its sales, marketing and distribution network which it believes that based on the quality of the Companys existing products, the Companys commitment to regulatory compliance and superior research and development resources, the Company believes that it will be able to achieve desired growth during 2020.

The Company expects to provide periodic updates on operational and financial reporting developments as warranted.

For more information regarding the Company please visit our website at

About Organicell Regenerative Medicine, Inc.

Organicell is a leading, fully integrated Company focused in the field of regenerative medicine. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicines to revolutionize the field of regenerative medicine. We believe that our ground-breaking research in the field of nanotechnology, specifically exosome enrichments and other micro vesicles, is the next frontier of stem cell-based therapeutics. Organicell is committed to creating life changing and lifesaving therapies for patients.

Our mission is to transform regenerative medicine by continuing to combine exosome technology with other synergistic therapies and become the healthcare technology incubator for biologic medicine.


The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Organicell Regenerative Medicine Inc., and its subsidiaries, plans and expectations, financial situation, the ability to retain key personnel, product acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, ability to expand sales and channels, and legislation or regulations affecting our operations and the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties. You are cautioned not to rely on these forward-looking statements. In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "intend", believes and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.

Management believes these forward-looking statements and the judgments upon which they are based to be reasonable, but they are not guarantees of future performance and involve numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, achievements or financial position to be materially different from any expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially from the forward-looking statements are set forth in our Form 10-K and other filings with the SEC. Other information can be obtained at The contents of the Companys website are not incorporated by reference in this Press Release.

Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press releases.

Organicell Regenerative Medicine Inc.4045 Sheridan Ave.Suite 239Miami Beach, FL 33140Website:http: http://www.organicell.comPhone: (888) 963-7881Email:

Read more:
Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status - GlobeNewswire

The Tiny Brain Cells That Connect Our Mental and Physical Health – WIRED

When enlarged under a high-resolution microscope, microglia resemble elegant tree branches with many slender limbs. As they pass by neurons, microglia extend and retract their tiny arm-like protrusions, tapping on each neuron as if to inquire, Are we good here? All okay? Or not okay?as a doctor might palpate a patients abdomen, or check reflexes by tapping on knees and elbows.

Back in 2004, Barres and Stevens were examining how synapses originally come to be pruned to form a healthy brain during early, normal development. Theyd recently discovered that immune molecules known as complement were sending out eat me signals from some brain synapses, and these synapsestagged with a kind of kiss of death signagewere destroyed. Think of the way you click and tag emails that you want deleted from your inbox. Your email servers software recognizes those tags, and when you click on the Trash icon, bing, theyre gone. Thats similar to what Stevens and Barres were seeing happen to brain synapses that were tagged by complement. They disappeared.

What they described happening in the brain, which they reported in the journal Cell in 2007, echoed a similar process that was well-understood to happen in the body. When a cell dies in a bodily organ, or if the bodys immune system senses a threatening pathogen, complement molecules tag those unwanted cells and invaders for removal. Then, a type of white blood cell known as macrophagesGreek for big eatersrecognizes the tag, engulfs the cell or pathogen, and destroys it. In the body, macrophages play a role in inflammation as well as in autoimmune diseases like rheumatoid arthritis and Guillain Barre. When activated, they can mistakenly go too far in their effort to engulf and destroy pathogens and spew forth a slew of inflammatory chemicals that begin to do harm to the bodys own tissue.

Stevens and Barres werent sure what was eating away at these tagged synapses, causing them to disappear in the brain, but Stevens had a hunch that it might have something to do with microglia.

We could see that when microglia sensed even the smallest damage or change to a neuron, they headed, spider-like, in that neurons direction, then they drew in their limbs and morphed into small, amoeba-like blobs, Stevens says. Soon after, those same synapses disappeared. Poof.

Could microglia be the culprit at the center of it all, the macrophage corollary in the brain, responding to eat me signals and pruning the brains circuitry during development? And what if this process was not only taking place in utero? Stevens wondered, when she first saw microglia behaving this way. What if it was also being mistakenly turned back on again later in life, during the teen years, or in adulthoodonly now its a bad thing and microglia are sometimes mistakenly engulfing and destroying healthy brain synapses too?

You can imagine how you could have too many synapses, or not enough synapse connectivity, Stevens says, her hands spreading wide with excitement. And you can imagine, given how our brain works, if that connectivity is even slightly off, that could potentially underlie a range of neuropsychiatric and cognitive disorders.

When she landed at Harvard, Stevens and her postdoc, Dori Schafer, tried to get a closer look at what microglia were up to in the brain. Schafer injected dye into the eyes of mice, which she then traced down from the neurons in the eye nerves and into the brain. This made the brains synapses glow bright fluorescent red. Microglia were stained fluorescent green. If they saw structuresthe synapsesglowing like red, fluorescent lit-up dots inside the bellies of the green microglia, they would know that microglia were eating synapses.

Six months into their efforts, Schafer came running into Stevenss office with photo images flapping in her hand. Theyre in there! she told Stevens. The synapses are inside the microglia! We can see it! It was such a high-five moment, Stevens recalls. Microglia were like tiny little Pac-Men in the brainand brain synapses were in the belly of the Pac-Men! We felt we were on to something really wonderful, really novel. This was deeply important in terms of looking ahead to microglias role in disease.

Read the original:
The Tiny Brain Cells That Connect Our Mental and Physical Health - WIRED

Novel mutations in stem cells of young donors can be passed to recipients – BioNews

20 January 2020

A new study suggests that rare harmful mutations in young healthy donors' stem cells can be passed on to recipients of stem cell transplants, potentially leading to health problems.

Stem cell transplants can be used to treat some blood disorders and cancers, such as acute myeloid leukaemia (AML), but can also have life-threatening complications such as cardiovascular problems and graft-versus-host disease (GvHD), where new immune cells from the donor attacks the patient's healthy cells.

'There have been suspicions that genetic errors in donor stem cells may be causing problems in cancer patients, but until now we didn't have a way to identify them because they are so rare,' said Dr Todd EDruley, Associate Professor of Paediatrics, Haematology and Oncology at Washington University School of Medicine, StLouis. 'This study raises concerns that even young, healthy donors' blood stem cells may have harmful mutations and provides strong evidence that we need to explore the potential effects of these mutations further.'Researchers analysed samples from patients with AML and their stem cell donors looking at 80 specific genes. The small pilot study identified at least one harmful genetic mutation in 11 of the 25 donors using an advanced sequencing technique. The donors ranged from 20 to 58 years old, with a median age of 26. Researchers later detected the harmful mutations present in donors within the recipients.

These extremely rare, harmful genetic mutations that are present in donors' stem cells do not cause any health problems to the donors, however, they may be passed on to the patients receiving stem cell transplants. Intense chemo- and radiation therapy is required prior to stem cell transplants and the immunosuppression given after the transplant unfortunately allows the rare mutation containing cells the opportunity to replicate quickly, which potentially can create health problems for the patients who receive them.

Co-author, Dr Sima TBhatt, Assistant Professor of Paediatrics, Haematology and Oncology also at Washington University, said 'Transplant physicians tend to seek younger donors because we assume this will lead to fewer complications. But we now see evidence that even young and healthy donors can have mutations that will have consequences for our patients. We need to understand what those consequences are if we are to find ways to modify them.'

The clinical implications of the findings need to be further studied. Dr Bhatt added: 'Now that we've also linked these mutations to GvHD and cardiovascular problems, we have a larger study planned that we hope will answer some of the questions posed by this one.'

Read the original here:
Novel mutations in stem cells of young donors can be passed to recipients - BioNews

Gains in Stem Cell Transplant Mortality Over Last 25 Years – MedPage Today

Outcomes have improved over the last quarter-century for patients undergoing allogeneic hematopoietic cell transplantation for treating their cancer, a single-center cohort study indicated.

Reported in the Annals of Internal Medicine, an adjusted analysis revealed that patients who had a transplant from 2013-2017 had a 34% lower risk of dying within 200 days after transplantation from a cause unrelated to disease relapse compared with patients who had a transplant from 2003-2007 (HR 0.66, 95% CI 0.48-0.89).

These patients from the later era also had an adjusted lower risk of disease relapse (HR 0.76, 95% CI 0.61-0.94), dying from relapse (HR 0.69, 95% CI 0.54-0.87), and dying from any cause (HR 0.66, 95% CI 0.56-0.78), according to George McDonald, MD, of Fred Hutchinson Cancer Research Center in Seattle, and colleagues.

The improvement in overall mortality was seen regardless of whether patients had myeloablative conditioning therapy versus reduced-intensity conditioning therapy or whether the transplant was from a matched sibling or unrelated donor.

"This is good news," Ryotaro Nakamura, MD, co-director of the Center for Stem Cell Transplantation at City of Hope in Duarte, California, told MedPage Today. Nakamura, who was not involved in the research, said the study shows at least "some progress" but the outcomes are still "far from perfect."

The results of the cohort study are based on data from 1,148 patients who had their first transplant from 2003-2007 and 1,131 patients who had their first transplant from 2013-2017, all of whom were treated at Seattle Cancer Care Alliance. Most patients had acute lymphocytic leukemia, acute myeloid leukemia, or myelodysplastic syndrome.

Although the results are from a single institution, Nakamura believes they are "largely applicable to the field in general."

These latest data show a trend in improved outcomes over not just the past 10 years, but 25. Previously, the study researchers showed in a 2010 study that 30% of patients who had a transplant from 1993-1997 died within 200 days after transplantation. The incidence has declined to 16% for patients from the 2003-2007 era and 11% for patients from the 2013-2017 era.

In addition, rate of relapse and overall mortality also improved over the three time periods, but the greatest improvement was seen for the rate of non-relapse mortality within 200 days. Relapse-related mortality was not assessed in the previous study for the 1993-1997 era.

Although the current cohort study cannot identify what caused the improvement in outcomes, "we can speculate about what changes in our transplant practices have contributed to better outcomes," McDonald told MedPage Today.

For starters, the risk of infection through 100 days after transplant was lower for patients treated from 2013-2017 compared with 2003-2007. These later-era patients had a lower risk of invasive mold infection (HR 0.55, 95% CI 0.33-0.92) and gram-negative bacteremia (HR 0.42, 95% CI 0.29-0.60).

Also, while the risk of any cytomegalovirus (CMV) infection did not decrease for later-era patients (HR 1.15, 95% CI 0.88-1.52), the risk of having a higher CMV viremia did. Specifically, the risk of CMV infection of more than 250 IU/mL (HR 0.78, 95% CI 0.55-1.10) or more than 1,000 IU/mL (HR 0.46, 95% CI 0.28-0.74) declined.

McDonald said that the lower frequency of serious infection may be due to the emergence of molecular methods of diagnosis and newer treatments. Also, the practice of treating graft-vs-host disease (GVHD) has changed.

Patients from the 2013-2017 era received lower initial doses of prednisone on average to treat GVHD (mean 0.58 vs 0.83 mg/kg, P<0.001) as well as had a lower total prednisone exposure (mean 0.08 vs 0.05, P<0.001). These reductions in prednisone allowed patients to avoid "many" of the side effects of prednisone, including loss of muscle mass, diabetes, and hypertension, explained McDonald.

In addition, the odds of a grade 3/4 GVHD event was lower among later-era patients compared with earlier-era patients (OR 0.63, 95% CI 0.46-0.86), as was the odds of chronic GVHD (OR 0.40, 95% CI 0.33-0.48).

Patients from the 2013-2017 period also had less frequent acute kidney injury, respiratory failure, and liver dysfunction during the first 100 days after transplant.

"The gradual shift from very high-dose conditioning therapy to less intense myeloablative therapy and to reduced-intensity conditioning was likely responsible for a reduction in damage to the liver, lungs, and kidneys over the last 10 years," McDonald said.

The study was primarily funded by the National Institutes of Health. Other funding sources included a grant from the American Cancer Society and individual awards. One study researcher was supported by a contract from the Patient-Centered Outcomes Research Institute. The funding sources did not influence the reporting of the study data.

Several study authors, including McDonald, reported having industry relationships.

Nakamura reported having no relevant conflicts of interest.


View original post here:
Gains in Stem Cell Transplant Mortality Over Last 25 Years - MedPage Today

Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN – Dove Medical Press

Hossein Derakhshankhah, 1, 2,* Samira Jafari, 1, 2,* Sajad Sarvari, 3 Ebrahim Barzegari, 4 Faezeh Moakedi, 5 Milad Ghorbani, 6 Behrang Shiri Varnamkhasti, 1 Mehdi Jaymand, 7 Zhila Izadi, 1, 8 Lobat Tayebi 9

1Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Zistmavad Pharmed Co., Tehran, Iran; 3Department of Pharmaceutical and Pharmacological Science, School of Medicine, West Virginia University, Morgantown, WV, USA; 4Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 5Department of Biochemistry and Molecular Biology, School of Medicine, West Virginia University, Morgantown, WV, USA; 6Department of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran; 7Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 8Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; 9Marquette University School of Dentistry, Milwaukee, WI 53201, USA

*These authors contributed equally to this work

Correspondence: Zhila Izadi; Lobat Tayebi Email;

Abstract: The advent of porous materials, in particular zeolitic nanoparticles, has opened up unprecedented putative research avenues in nanomedicine. Zeolites with intracrystal mesopores are low framework density aluminosilicates possessing a regular porous structure along with intricate channels. Their unique physiochemical as well as physiological parameters necessitate a comprehensive overview on their classifications, fabrication platforms, cellular/macromolecular interactions, and eventually their prospective biomedical applications through illustrating the challenges and opportunities in different integrative medical and pharmaceutical fields. More particularly, an update on recent advances in zeolite-accommodated drug delivery and the prevalent challenges regarding these molecular sieves is to be presented. In conclusion, strategies to accelerate the translation of these porous materials from bench to bedside along with common overlooked physiological and pharmacological factors of zeolite nanoparticles are discussed and debated. Furthermore, for zeolite nanoparticles, it is a matter of crucial importance, in terms of biosafety and nanotoxicology, to appreciate the zeolite-bio interface once the zeolite nanoparticles are exposed to the bio-macromolecules in biological media. We specifically shed light on interactions of zeolite nanoparticles with fibrinogen and amyloid beta which had been comprehensively investigated in our recent reports. Given the significance of zeolite nanoparticles interactions with serum or interstitial proteins conferring them new biological identity, the preliminary approaches for deeper understanding of administration, distribution, metabolism and excretion of zeolite nanoparticles are elucidated.

Keywords: zeolite, mesoporous, nanostructure, biosafety, biomedical applications

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more here:
Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN - Dove Medical Press

Cell therapy trialed in mice offers diabetes treatment hope – SelectScience

New cell treatment could help maintain healthy blood sugar levels

A new cell treatment to enhance islet transplantation could help maintain healthy blood sugar levels in Type 1 diabetes without the need for multiple transplants of insulin producing cells or regular insulin injections, research suggests.

In Type 1 diabetes the insulin-producing cells of the pancreas are destroyed. Insulin injections maintain health but blood glucose levels can be difficult to control. Currently in the UK it is estimated that approximately 400,000 people in the UK have type 1 diabetes.

The current recommendation for people with type 1 diabetes who have lost awareness of low blood glucose levels is the transplantation of islets the insulin producing part of the pancreas.

A study in mice found that transplanting a combination of islets with connective tissue cells found in umbilical cords known as stromal cells - could potentially reduce the number of pancreases required for the procedure.

Mice that received the islet-stromal cell combination were found to have better control of blood glucose and less evidence of rejection of islets after seven weeks, compared to those that received islets alone.

In humans, more than two donor pancreases, which are scarce, are often needed because islets can be rejected and are slow to form new blood supplies.

Therefore, multiple islet transplantations and anti-rejection medication are required to control blood sugar levels in people with Type 1 diabetes. Scientists at the University of Edinburgh hope their findings could be a way of overcoming these issues.

The researchers found that islets combined with stromal cells successfully returned normal blood glucose levels just three days after transplantation.

Other studies have used cells sourced from bone marrow and fat. This is the first to use stem cells from umbilical cords and has produced superior results.

The research is published in the journal Science Translational Medicine and funded by Chief Scientist Office in Scotland and Diabetes UK.

Shareen Forbes, Professor of Diabetic Medicine at the University of Edinburgh and Lead Physician for the Islet Transplant Program in Scotland, said: Should this research prove successful in humans, we could reduce the number of islets needed to control blood sugar levels using this co-transplantation approach. This would mean more people with Type 1 diabetes could be treated using islet transplantation while significantly reducing the waiting time on the transplant list.

John Campbell, Professor and Associate Director Tissues, Cells & Advanced Therapeutics at the Scottish National Blood Transfusion Service has said that further work is needed to establish the long-term safety of using this type of stromal cell in this setting before proceeding to clinical trials in humans.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, said: Islet transplants have been life changing for some people with Type 1 diabetes, treating dangerous hypo unawareness. But there currently arent enough donated pancreases to go around, and the procedure itself isnt yet as effective as it could be.

This new research from the University of Edinburgh is a promising step forward, and one we hope will lead to islet transplants becoming both more effective and more widely available in the future.

Register for your free SelectScience membership today to receive the latest editorial articles and technology news direct to your inbox>>

Cell therapy trialed in mice offers diabetes treatment hope - SelectScience

Scientists Image Heart RNA Structure for the First Time – Diagnostic and Interventional Cardiology

January 20, 2020 Scientists at Los Alamos and international partners have created the first 3-D images of a special type of RNA molecule that is critical for stem cell programming and known as the dark matter of the genome.

As far as we know, said corresponding author Karissa Sanbonmatsu, Ph.D.,this is the first full 3-D structural study of any long, non-coding RNA (lncRNA) other than a partial structure. Sanbonmatsu is a structural biologist at Los Alamos National Laboratory. A better understanding of these RNAs could lead to new strategies in regenerative medicine for people with heart conditions due to cardiovascular disease or aging.

The team used a technique called small angle X-ray scattering (SAXS) that reveals the 3-D envelope of the RNA molecule, according to Trushar Patel, a Canadian professor on the team. Next, with the help of machine learning and high-performance computing, they made atomistic models to fit inside the envelopes this included the creation of an atomistic model that is also the longest of an isolated RNA (636 nucleotides) to date, said Doo Nam Kim, lead author on the Nature Communications paper.[1]

Our work represents the first step in showing that these difficult-to-image RNAs do possess 3-D structures, and that these molecular structures may very well determine how they operate, said Sanbonmatsu. The RNA studied is called Braveheart it triggers the transformation of stem cells into heart cells, she said.

Before the human genome was sequenced in 2000, it was thought that it mostly contained instructions for proteins, the workhorse molecules of human cells. Scientists were shocked to discover that less than 10 percent of the genome encoded proteins. Ever since, the other 90 percent was deemed to be junk DNA or dark matter. Enter RNA, the molecular cousin of DNA. Scientists originally assumed the main purpose of RNA was simply to coordinate as a messenger for DNA in the synthesis of proteins. However, it has recently been shown that more than 90 percent of the genome encodes a new and mysterous class of RNAs, called long non-coding RNA molecules (lncRNA).

These RNA molecules help to control the turning on and off of genes; their malfunction causes birth defects, autism and even cancer in some cases. They are also key to reprogramming adult stem cells. Even though the molecules make up 90 percent of the genome, scientists have almost no idea how they work, or even what they look like. In this study, one of the largest RNA-only 3-D studies, the new 3-D images sets the stage for future studies that will shed more light on how they control genes.

Funding for this project was provided by the National Institutes of Health (NIH), Los Alamos Institutional Computing and Los Alamos Laboratory Directed R&Dand Diamond Light Source (U.K.).

Learn more about theSanbonmatsu Team at Los Alamos.


1.Karissa Y. Sanbonmatsu, Doo Nam Kim and Scott P. Hennelly of Los Alamos National Laboratory and New Mexico Consortium; Bernhard C. Thiel and Ivo L. Hofacker of University of Vienna, Austria; Tyler Mrozowich and Trushar R. Patel of University of Lethbridge, Canada. Zinc-finger protein CNBP alters the 3-D structure of lncRNA Braveheart in solution Authors: Nature Communications, DOI 10.1038/s41467-019-13942-4.

Here is the original post:
Scientists Image Heart RNA Structure for the First Time - Diagnostic and Interventional Cardiology

Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News – Dagoretti News

In 2019, the market size of Stem Cell Assay Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Assay .

This report studies the global market size of Stem Cell Assay , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @

This study presents the Stem Cell Assay Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Assay history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Assay market, the following companies are covered:

growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request For Discount On This Report @

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Assay product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Assay , with price, sales, revenue and global market share of Stem Cell Assay in 2017 and 2019.

Chapter 3, the Stem Cell Assay competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Assay breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Assay market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Assay sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Continued here:
Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News - Dagoretti News